Arvinas (ARVN) announced it has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC androgen receptor degrader
Arvinas (ARVN) announced it has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC androgen receptor degrader
After Alpine Immune Sciences (ALPN) and Vertex Pharmaceuticals (VRTX) announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share, or
Novartis is cutting up to 680 jobs in its development organization, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday, according to Reuters. Around 440
Novartis announced new data demonstrating the early addition of twice-yearly Leqvio to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol in
Novartis announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for